PostedSeptember 16, 2021, 5:07 PM
A study will be carried out in the canton of Vaud to test a vaccine against a fatal fever. With, in the long term, a technology that could be used to fight against Covid.
Unisanté is conducting a clinical study on a new type of vaccine inducing cellular immunity to fight dengue, according to a statement. This potentially fatal viral infection affects 3.9 billion people per year. It is transmitted by a mosquito and mainly affects tropical areas, although the Mediterranean basin is now affected due to global warming. No treatment exists.
In Switzerland, it is one of the most frequent causes of fever when returning from a trip. The incidence of dengue has increased eightfold over the past twenty years.
Two deaths per hour
The World Health Organization (WHO) estimates that the dengue virus causes nearly half a billion infections per year, leads to one hospitalization per minute and two deaths per hour. Due to the coronavirus pandemic, there has been an upsurge in cases.
Developed in England by Emergex Vaccines, the PepGNP-Dengue vaccine works by killing infected cells rather than producing an antibody-based response like conventional vaccines. In the case of dengue, the antibodies are indeed sometimes protective, but can also prove to be aggravating in people re-exposed to the virus, a phenomenon known as “antibody-dependent strengthening”. This new technology offers real hope, according to Unisanté.
And soon a vaccine against the Covid?
In order to assess the safety of this vaccine administered for the first time in humans, Unisanté was commissioned to carry out a phase I clinical study, to determine whether the vaccine does not induce severe adverse side effects in volunteers. healthy.
Approved by the Ethics Commission of the Canton of Vaud and Swissmedic, the study will be carried out in Lausanne with the participation of the Clinical Research Center (CRC) of the CHUV-UNIL and the immunology and allergy service of the CHUV. Lasting 6 months, it will be carried out on 26 volunteers. A vaccine against COVID-19 using the same technology will be tested at Unisanté following this study. Like the dengue vaccine, it may be more effective against variants of SARS-CoV-2.